| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/HP.2011.10.918 |
| P698 | PubMed publication ID | 22056819 |
| P2093 | author name string | Scott W Yates | |
| P2860 | cites work | Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review | Q37661890 |
| Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism | Q37827863 | ||
| Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation | Q37832237 | ||
| Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor | Q37841256 | ||
| Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists? | Q37858373 | ||
| Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence | Q40310174 | ||
| Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study | Q41710562 | ||
| Diagnosing atrial fibrillation in general practice | Q42411572 | ||
| Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment | Q43138653 | ||
| Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale | Q43138658 | ||
| Epidemiology of subtherapeutic anticoagulation in the United States | Q43209294 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| Quality of care for atrial fibrillation among patients hospitalized for heart failure | Q43271850 | ||
| Increasing prevalence of atrial fibrillation and flutter in the United States | Q44353676 | ||
| Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation | Q46157364 | ||
| Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors | Q46874348 | ||
| Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry | Q46930303 | ||
| 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. | Q52854133 | ||
| Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme | Q57086723 | ||
| ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation | Q22306351 | ||
| Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...] | Q27648707 | ||
| A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin | Q28195787 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q28303699 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
| Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study | Q34038150 | ||
| Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation | Q34118769 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 | ||
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial | Q34624280 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis | Q35982540 | ||
| Status of the epidemiology of atrial fibrillation | Q36464561 | ||
| Effect of study setting on anticoagulation control: a systematic review and metaregression | Q36473615 | ||
| Death and disability from warfarin-associated intracranial and extracranial hemorrhages | Q36501858 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apixaban | Q414462 |
| atrial fibrillation | Q815819 | ||
| P304 | page(s) | 7-16 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Hospital Practice | Q5908551 |
| P1476 | title | Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence | |
| P478 | volume | 39 |
| Q38189788 | The new factor Xa inhibitor: Apixaban | cites work | P2860 |
Search more.